Mathé G, Triana K, Pontiggia P, Blanquet D, Hallard M, Morette C
Institut de Cancérologie et d'Immunologie et Hôpital Suisse de Paris, Issy-les-Moulineaux, France.
Biomed Pharmacother. 1998;52(9):391-6. doi: 10.1016/S0753-3322(99)80007-9.
Two virostatics which we discovered in 1990, acriflavine (ACF) and hydroxy-methyl-ellipticine (HEL) and shown active on HIV1 resistant to AZT have been introduced into combinations of four virostatics selected among ten available: themselves, plus zidovudine, zalcitabine, didanosine, lamivudine, stavudine, saquinavir, ritonavir, indinavir, the combinations were applied in 3-week sequences, differing from each other by drug rotation. Those which contained ACF may have more often a CD34 decrease than those containing neither ACF nor HEL, and they present more often a CD4 increase. No significant difference as far as side effects or beneficial effects could be detected after 18 months to 6 years, between sequences containing ACF or HEL or both, and sequences not containing any one of them.
我们于1990年发现的两种病毒抑制剂，吖啶黄素（ACF）和羟甲基椭圆玫瑰树碱（HEL），对耐齐多夫定的HIV1显示出活性，已被引入从十种可用药物中选出的四种病毒抑制剂组合中：它们自身，加上齐多夫定、扎西他滨、去羟肌苷、拉米夫定、司他夫定、沙奎那韦、利托那韦、茚地那韦，这些组合按3周序列应用，通过药物轮换彼此不同。含有ACF的组合比既不含ACF也不含HEL的组合更常出现CD34降低，且它们更常出现CD4增加。在18个月至6年之后，含有ACF或HEL或两者的序列与不含有其中任何一种的序列之间，在副作用或有益效果方面未检测到显著差异。
